Paper ties EZH1, vHL to synthetic lethality in RCC

In a paper published in Science Translational Medicine, scientists showed that inhibition of enhancer of zeste homolog 1 (EZH1) prevented proliferation in von Hippel-Lindau tumor suppressor (vHL)-mutant clear cell renal cell carcinoma, suggesting that EZH1 could be targeted to treat the indication.

The paper's authors included researchers from Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, The Broad Institute of MIT and Harvard, and Howard Hughes Medical Institute...